BioNTech SE - ADR
NASDAQ:BNTX 11:28:02 AM EDT
| Market Cap (Intraday) | 32.91B |
| Current PE | 2.80 |
| Forward PE | 4.06 |
| 2yr Forward PE | 7.56 |
| 10-Day MA | $134.01 |
| 50-Day MA | $150.04 |
| 200-Day MA | $163.25 |
BioNTech SE - ADR Stock, NASDAQ:BNTX
An der Goldgrube 12, Mainz, Rheinland-Pfalz 55131
Germany
Phone: +49.6131.9084.0
Number of Employees: 3082
Description
BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.